|
UW17114
|
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
|
Open |
|
ANHL12P1
|
A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) (IND#117117) |
Open |
|
AHOD1331
|
A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed High Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents |
Open |
|
ALTE1631
|
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621F
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621SC
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
APEC1621I
|
NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes |
Open |
|
UW17094
|
Nurse-Led Parent Educational Discharge Support Strategies (PEDSS) for Children Newly Diagnosed with Cancer
|
Open |
|
UW13090
|
TCR-a/b+ and CD19+ depleted KIR/KIR ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors |
Open |
UW Carbone
